Literature DB >> 27571145

Antiglutamatergic therapy for multiple sclerosis?

Reinhard Hohlfeld1, Martin Kerschensteiner2.   

Abstract

Entities:  

Year:  2016        PMID： 27571145     DOI： 10.1016/S1474-4422(16)30163-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  2 in total

1.  β1-Integrin- and KV1.3 channel-dependent signaling stimulates glutamate release from Th17 cells.

Authors:  Katharina Birkner; Beatrice Wasser; Tobias Ruck; Carine Thalman; Dirk Luchtman; Katrin Pape; Samantha Schmaul; Lynn Bitar; Eva-Maria Krämer-Albers; Albrecht Stroh; Sven G Meuth; Frauke Zipp; Stefan Bittner
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 2.  FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models.

Authors:  Ranjithkumar Rajendran; Gregor Böttiger; Christine Stadelmann; Srikanth Karnati; Martin Berghoff
Journal:  Cells       Date:  2021-04-13       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.